文献速递免疫规划传染病防控与疫情报告

塞内加尔儿童季节性灭活流感疫苗与灭活脊灰疫苗的免疫原性:整群随机试验结果

Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial.
PubMed 文献 · Vaccine · 2020-10-02

该研究基于2009年塞内加尔农村儿童整群随机试验,评估三价灭活流感疫苗(IIV3)和灭活脊灰疫苗(IPV)的免疫原性。结果显示IIV3对A/H1N1和A/H3N2血清转化率较高,对B/Yamagata较低, youngest年龄组应答最低;基线血清阳性是IIV应答的效应修饰因子。IPV组基线脊灰抗体阳性率高且接种后应答适当。

要点

  • IIV3对A/H1N1和A/H3N2血清转化率为74-87%,对B/Yamagata为54-79%。
  • youngest年龄组(6-35月龄)IIV应答最低,建议疫苗初种儿童完成两剂系列。
  • 基线HAI≥1:10是IIV应答的效应修饰因子,基线血清阳性者血清保护率更高。

核心结论

  • IIV3和IPV在塞内加尔儿童中具有免疫原性。
  • 数据强调疫苗初种儿童完成两剂IIV3系列的重要性。

研究设计与样本

  • 2009年在塞内加尔农村开展的整群随机试验(NCT00893906)的免疫原性子研究。
  • 评估三个年龄组(6-35月龄、3-5岁、6-8岁)接种后的血凝抑制(HAI)和脊灰抗体滴度。
  • 所有儿童均为IIV初种,均接种两剂,但6-8岁组仅评估第一剂后滴度。

主要发现

  • 血清转化率(4倍升高或<1:10升至≥1:40):A/H1N1为74-87%,A/H3N2为76-87%,B/Yamagata为54-79%。
  • 血清保护率(HAI≥1:40):A/H1N1为79-88%,A/H3N2为88-96%,B/Yamagata为52-74%。
  • IIV应答在 youngest年龄组最低,3-5岁组两剂后与6-8岁组一剂后应答相当。
  • 基线血清阳性(HAI≥1:10)是IIV应答的效应修饰因子。
  • 采用儿童IIV评估推荐的血清保护滴度(HAI≥1:160),基线血清阳性者中69%对A/H1N1和A/H3N2均达到血清保护,基线血清阴性者中A/H1N1为11%、A/H3N2为22%。

关键数值与推荐

  • 血清转化定义:4倍滴度升高或从<1:10升至≥1:40。
  • 血清保护定义(常规):HAI滴度≥1:40。
  • 儿童IIV评估推荐血清保护滴度:HAI≥1:160。
  • 基线血清阳性定义:HAI滴度≥1:10。

临床怎么用

  • 疫苗初种儿童应完成两剂IIV3系列以保障免疫应答。
  • 评估儿童IIV免疫原性时可参考HAI≥1:160的血清保护阈值。
  • 基线血清状态有助于解释IIV应答差异。

局限性

  • 6-8岁组仅评估第一剂后滴度,未评估两剂后应答。
  • 研究于2009年H3N2疫苗不匹配年度开展,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data on influenza vaccine immunogenicity in children are limited from tropical developing countries. We recently reported significant, moderate effectiveness of a trivalent inactivated influenza vaccine (IIV) in a controlled, cluster-randomized trial in children in rural Senegal during 2009, a year of H3N2 vaccine mismatch (NCT00893906). We report immunogenicity of IIV3 and inactivated polio vaccine (IPV) from that trial. We evaluated hemagglutination inhibition (HAI) and polio antibody titers in response to vaccination of three age groups (6 through 35 months, 3 through 5 years, and 6 through 8 years). As all children were IIV naïve, each received two vaccine doses, although titers were assessed after only the first dose for subjects aged 6 through 8 years. Seroconversion rates (4-fold titer rise or increase from <1:10 to ≥1:40) were 74-87% for A/H1N1, 76-87% for A/H3N2, and 54-79% for B/Yamagata. Seroprotection rates (HAI titer ≥ 1:40) were 79-88% for A/H1N1, 88-96% for A/H3N2, and 52-74% for B/Yamagata. IIV responses were lowest in the youngest age group, and they were comparable between ages 3 through 5 years after two doses and 6 through 8 years after one dose. We found that baseline seropositivity (HAI titer ≥ 1:10) was an effect modifier of IIV response. Using a seroprotective titer (HAI titer ≥ 1:160) recommended for IIV evaluation in children, we found that among subjects who were seropositive at baseline, 69% achieved seroprotection for both A/H1N1 and A/H3N2, while among those who were seronegative at baseline, seroprotection was achieved in 11% for A/H1N1 and 22% for A/H3N2. The IPV group had high baseline polio antibody seropositivity and appropriate responses to vaccination. Our data emphasize the importance of a two-dose IIV3 series in vaccine naïve children. IIV and IPV vaccines were immunogenic in Senegalese children.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Niang M, Deming ME, Goudiaby D, et al. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial. Vaccine. 2020. PMID: 33012603. doi:10.1016/j.vaccine.2020.09.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。